Different spontaneous pulmonary metastasis inhibitions against Lewis lung carcinoma in mice by bisdioxopiperazine compounds of different treatment schedules

Scientia Pharmaceutica

Volumn 78, Issue 1, 2010, Pages 13-20

  Lu, Da Yong ^a   Wu, Fu Geng ^b   Zhen, Zu Ming ^b   Lu, Ting Ren ^a   Wu, Hong Ying ^a   Che, Jin Yu ^a   Xu, Bin ^b  

^a SHANGHAI UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Bisdioxopiperazine compounds; Cancer chemotherapy; Neoplasm metastasis; Probimane; Razoxane

Indexed keywords

BIMOLANE; PIPERAZINE DERIVATIVE; PROBIMANE; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; DRUG STRUCTURE; IMMUNOMODULATION; LD 50; LEWIS CARCINOMA; LUNG METASTASIS; LUNG PARENCHYMA; METASTASIS INHIBITION; MOUSE; NONHUMAN;

EID: 77749240331     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.0910-16     Document Type: Article

References (27)

1. Taraboletti G, Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol. 2001; 1: 378-384. doi:10.1016/S1471-4892(01)00065-0
2. Sava G, Bergamo A. Drug control of solid tumour metastases: a critical view. Anticancer Res. 1999; 19: 1117-1124. PMid:10368662
3. Lu DY, Huang M, Zhou J, Ding J. Recent advances in anti-metastatic drug development. Acta Pharmacol Sin. 2006; 27 (Suppl): 66-67.
4. Verheul HMW, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Rev Cancer. 2007; 7: 475-485. doi:10.1038/nrc2152
5. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980; 283: 139-146. doi:10.1038/283139a0
6. Fidler IJ Critical factors in the biology of human cancer metastasis: Twenty-eight GHA Clowes memorial award lecture. Cancer Res. 1990; 50: 6130-6138. PMid:1698118
7. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nature Rev Cancer. 2003; 3: 453-458. doi:10.1038/nrc1098
8. Lu DY, Wu Y, Cao JY. [Effects and mechanisms of anti-metastatic drugs]. Henan Yixue Yanjiu [Henan Med Res]. 1996; 5: 357-358.
9. Hellmann K, Burrage K. Control of malignant metastases by ICRF-159. Nature. 1969; 224: 273-275. doi:10.1038/224273a0
10. Herman EH, Witiak DT, Hellmann K, Waradek VS. Properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Adv Pharmacol Chemother. 1982; 19: 249-290. doi:10.1016/S1054-3589(08)60025-3
11. Ji RY. Probimane. Drugs Future. 1988; 13: 418-419.
12. Lu DY, Xu B, Ding J. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. BMC Pharmacol. 2004; 4: 32. doi:10.1186/1471-2210-4-32
13. 2/M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. BMC Pharmacol. 2005; 5: 11. doi:10.1186/1471-2210-5-11
14. Lu DY, Huang M, Xu CH, Zhu H, Xu B, Ding J. Medicinal Chemistry of probimane and MST- 16: comparison of anticancer effects between bisdioxopiperazines. Med Chem. 2006; 2: 369- 375. doi:10.2174/157340606777724095
15. Ren YF, Otter GM, Schmit FA. Further evaluation of bimolane and analogs as potential antitumor agents. Eur J Cancer Clin Oncol. 1985; 21: 493-497. doi:10.1016/0277-5379(85)90043-4
16. Li XT, Hutchinson GE, Pym BA, Finch M, Hellmann K. Effect of AT-1727 on growth and metastasis of murine tumours. Eur J Cancer Clin Oncol. 1983; 19: 283-287. doi:10.1016/0277-5379(83)90428-5
17. Yue XF, Wu FG, Xu B. [Effects of oxalysine on pulmonary metastasis of Lewis lung carcinoma in mice]. Acta Pharmacol Sin. 1985; 6: 198-200. PMid:2943127
18. Salsbury AJ, Burrage K, Hellmann K. Histological analysis of the antimetastatic effect of (±)-1,2-bis(3,5-dioxopiperazin-1-yl) propane. Cancer Res. 1974; 34: 843-849. PMid:4814997
19. Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res. 2000; 6: 4697-4704. PMid:11156222
20. Hellmann K. Dynamics of tumor angiogenesis: effect of razoxane- induced growth rate slowdown. Clin Exp Metastasis. 2003; 20: 95-102. doi:10.1023/A:1022632413888
21. 125I-fibrinogen to two leukaemia cell lines in vitro. J Int Med Res. 2004; 32: 488-491. PMid:15458280
22. Lu DY, Liang G, Zhang MJ, Xu B. Serum contents of sialic acids in mice bearing different tumors. Chin Sci Bull (Eng). 1994; 39: 1220-1223.
23. James SE, Salsbury AJ. Effect of (±)-1,2-bis(3,5-dioxopiperazin-1- yl) propane non tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res. 1974; 34: 839-842. PMid:4814996
24. 14C labeled at dioxopiperazine or methyl morphorline group of probimane by whole body autoradiography]. Acta Pharmacol Sin. 1993; 14: 171-173. PMid:8352014
25. Lu DY, Zhang SY, Chen RT, Zhang X, Xu B. [Studies on antitumor action and absorption, distribution and excretion of probimane]. Chin J Pharmaceut. 1989; 20, 327-330.
26. Lu DY, Chen EH, Cao JY, Zhou JJ, Shen ZM, Xu B, Horie K. [Comparison between probimane and razoxane on inhibiting calmodulin activity of rabbit erythrocyte membrane]. Chin J Pharmacol Toxicol. 2001; 15: 76-78.
27. Fidler IJ. Macrophages and metastasis-a biological approach to cancer therapy: presidential address. Cancer Res. 1985; 45: 4714-4726. PMid:2992766